Top-Down Quantitative Proteomics Identified Phosphorylation of Cardiac Troponin I as a Candidate Biomarker for Chronic Heart Failure
Jiang Zhang, Moltu J. Guy, Holly S. Norman et al. · Journal of Proteome Research · 2011
The rapid increase in the prevalence of chronic heart failure (CHF) worldwide underscores an urgent need to identify biomarkers for the early detection of CHF. Post-translational modifications (PTMs) are associated with many critical signaling events during disease progression and thus offer a plethora of candidate biomarkers. We have employed a top-down quantitative proteomics methodology for comprehensive assessment of PTMs in whole proteins extracted from normal and diseased tissues. We systematically analyzed 36 clinical human heart tissue samples and identified phosphorylation of cardiac troponin I (cTnI) as a candidate biomarker for CHF. The relative percentages of the total phosphorylated cTnI forms over the entire cTnI populations (%P(total)) were 56.4 ± 3.5%, 36.9 ± 1.6%, 6.1 ± 2.4%, and 1.0 ± 0.6% for postmortem hearts with normal cardiac function (n = 7), early stage of mild hypertrophy (n = 5), severe hypertrophy/dilation (n = 4), and end-stage CHF (n = 6), respectively. In fresh transplant samples, the %P(total) of cTnI from nonfailing donor (n = 4), and end-stage failing hearts (n = 10) were 49.5 ± 5.9% and 18.8 ± 2.9%, respectively. Top-down MS with electron capture dissociation unequivocally localized the altered phosphorylation sites to Ser22/23 and determined the order of phosphorylation/dephosphorylation. This study represents the first clinical application of top-down MS-based quantitative proteomics for biomarker discovery from tissues, highlighting the potential of PTMs as disease biomarkers.
Cited by 193 works. doi:10.1021/pr200258m
Authors
- Jiang Zhang
- Moltu J. Guy
- Holly S. Norman
- Yichen Chen
- Qingge Xu
- Xintong Dong
- Hüseyin Güner
- Sijian Wang
- Takushi Kohmoto
- Ken H. Young
- Richard L. Moss
- Ying Ping Ge
References
- The Human Plasma Proteome
- The Global Burden of Chronic Diseases
- Protein biomarker discovery and validation: the long and uncertain path to clinical utility
- Proteomic analysis of post-translational modifications
- Calcium-activated neutral protease (calpain) system: structure, function, and regulation.
- Electron Capture Dissociation for Structural Characterization of Multiply Charged Protein Cations
- Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes
- Biomarkers of Cardiovascular Disease
- Top Down versus Bottom Up Protein Characterization by Tandem High-Resolution Mass Spectrometry
- Mining the plasma proteome for cancer biomarkers